HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

HUTCHMED Limited announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to HMPL-523, a novel, investigational spleen tyrosine kinase inhibitor, for the treatment of chronic adult primary immune thrombocytopenia patients who have received at least one prior therapy.